Hinge Health (HNGE) CEO & 10% owner logs 166,665-share conversion, stock sales

Rhea-AI Filing Summary

Hinge Health, Inc. CEO, Co-Founder, director and 10% owner reported insider transactions dated 01/05/2026. The reporting person converted 166,665 shares of Class B Common Stock into 166,665 shares of Class A Common Stock at an exercise price of $0, then sold 122,368 Class A shares at a weighted average price of $46.2458 and a further 44,297 Class A shares at a weighted average price of $46.7664.

The sales were made under a Rule 10b5‑1 trading plan adopted on September 11, 2025. Following these transactions, indirect holdings include 35,470 Class A shares held by a spouse, and derivative holdings include 14,376,762 shares of Class B Common Stock and 515,705 Class A shares through a spouse, each Class B share being convertible into one Class A share as described in the company’s charter.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Perez Daniel Antonio

(Last) (First) (Middle)

C/O HINGE HEALTH, INC.

455 MARKET STREET, SUITE 700

(Street)

SAN FRANCISCO CA 94015

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & Co-Founder

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/05/2026		C		166,665	A	$0	166,665	D
Class A Common Stock	01/05/2026		S(1)		122,368	D	$46.2458(2)	44,297	D
Class A Common Stock	01/05/2026		S(1)		44,297	D	$46.7664(3)	0	D
Class A Common Stock								35,470	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Class B Common Stock	(4)	01/05/2026		C			166,665	(4)	(4)	Class A Common Stock	166,665	$0	14,376,762	D
Class B Common Stock	(4)							(4)	(4)	Class A Common Stock	515,705		515,705	I	By Spouse

Explanation of Responses:

1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2025.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $45.47 and the highest price at which shares were sold was $46.46. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Represents the weighted average sale price. The lowest price at which shares were sold was $46.47 and the highest price at which shares were sold was $46.97. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

4. Each share of Class B Common Stock is convertible into one share of the lssuer's Class A Common Stock at any time, at the election of the holder or automatically upon certain transfers, whether or not for value, or upon the occurrence of certain events or conditions described in the Issuer's Amended and Restated Certificate of Incorporation.

	/s/ James Budge, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Hinge Health (HNGE) report on January 5, 2026?

The reporting person converted 166,665 Class B Common shares into Class A Common shares at $0 and sold 122,368 Class A shares at a weighted average price of $46.2458 and 44,297 Class A shares at a weighted average price of $46.7664.

Who is the insider involved in this Hinge Health (HNGE) Form 4 filing?

The reporting person is the company’s CEO & Co-Founder, and also a director and 10% owner of Hinge Health, Inc.

Were the Hinge Health (HNGE) share sales made under a Rule 10b5-1 plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5‑1 trading plan adopted by the reporting person on September 11, 2025.

What prices were received for the Hinge Health (HNGE) Class A shares sold?

The first sale had a weighted average price of $46.2458, with individual prices ranging from $45.47 to $46.46. The second sale had a weighted average price of $46.7664, with prices ranging from $46.47 to $46.97.

How many Hinge Health (HNGE) shares does the insider and spouse hold after these transactions?

After the reported transactions, indirect non-derivative holdings include 35,470 Class A shares held by the spouse. Derivative holdings include 14,376,762 Class B Common shares directly and 515,705 Class A shares through the spouse.

How are Hinge Health (HNGE) Class B shares treated relative to Class A shares?

Each share of Class B Common Stock is convertible into one share of Class A Common Stock at any time at the election of the holder or automatically upon certain transfers or events described in the company’s Amended and Restated Certificate of Incorporation.